Ztalmy (Ganaxolone) Patent Expiration, LOE Window & CMS Spending

Ztalmy (Ganaxolone) by Immedica Ab: FDA Orange Book LOE 2042-09-30, 0 AB generics, $24.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorImmedica Ab
FDA Application & PathwayN215904 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2042-09-30
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$24.1M
2024 Medicare Part D Spend$2.0M
2024 Medicaid Spend$22.2M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.9% 2-yr change)